[1]
|
Dodiuk-Gad, R.P., Chung, W.H., Valeyrie-Allanore, L., et al. (2015) Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. American Journal of Clinical Dermatology, 16, 475-493.
https://doi.org/10.1007/s40257-015-0158-0
|
[2]
|
曾宪涛, 黄伟, 田国祥. Meta分析系列之九: Meta分析的质量评价工具[J]. 中国循证心血管医学杂志, 2013, 5(1): 3-5.
|
[3]
|
Singh, G.K., Chatterjee, M. and Verma, R. (2013) Cyclosporine in Stevens Johnson Syndrome and Toxic Epidermal Necrolysis and Retrospective Comparison with Sys-temic Corticosteroid. Indian Journal of Dermatology, Venereology and Leprology, 79, 686-692. https://doi.org/10.4103/0378-6323.116738
|
[4]
|
Kirchhof, M.G., Miliszewski, M.A., Sikora, S., et al. (2014) Ret-rospective Review of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Treatment Comparing Intravenous Im-munoglobulin with Cyclosporine. Journal of the American Academy of Dermatology, 71, 941-947. https://doi.org/10.1016/j.jaad.2014.07.016
|
[5]
|
Lee, H.Y., Fook-Chong, S., Koh, H.Y., et al. (2017) Cyclosporine Treatment for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Retrospective Analysis of a Cohort Treated in a Specialized Referral Center. Journal of the American Academy of Dermatology, 76, 106-113. https://doi.org/10.1016/j.jaad.2016.07.048
|
[6]
|
Mohanty, S., Das, A., Ghosh, A., et al. (2017) Effectiveness, Safety and Tolerability of Cyclosporine versus Supportive Treatment in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Record-Based Study. Indian Journal of Dermatology, Venereology and Leprology, 83, 312-316. https://doi.org/10.4103/ijdvl.IJDVL_201_16
|
[7]
|
Stella, M., Clemente, A., Bollero, D., et al. (2007) Toxic Epi-dermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS): Experience with High-Dose Intravenous Immuno-globulins and Topical Conservative Approach. A Retrospective Analysis. Burns: Journal of the International Society for Burn Injuries, 33, 452-459.
https://doi.org/10.1016/j.burns.2006.08.014
|
[8]
|
Yang, Y., Xu, J., Li, F., et al. (2009) Combination Therapy of Intravenous Immunoglobulin and Corticosteroid in the Treatment of Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome: A Retrospective Comparative Study in China. International Journal of Dermatology, 48, 1122-1128. https://doi.org/10.1111/j.1365-4632.2009.04166.x
|
[9]
|
Zhu, Q.Y., Ma, L., Luo, X.Q., et al. (2012) Toxic Epi-dermal Necrolysis: Performance of SCORTEN and the Score-Based Comparison of the Efficacy of Corticosteroid Therapy and Intravenous Immunoglobulin Combined Therapy in China. Journal of Burn Care & Research, 33, e295-e308. https://doi.org/10.1097/BCR.0b013e318254d2ec
|
[10]
|
Jagadeesan, S., Sobhanakumari, K., Sadanandan, S.M., et al. (2013) Low Dose Intravenous Immunoglobulins and Steroids in Toxic Epidermal Necrolysis: A Prospective Comparative Open-Labelled Study of 36 Cases. Indian Journal of Dermatology, Venereology and Leprology, 79, 506-511. https://doi.org/10.4103/0378-6323.113080
|
[11]
|
Lalosevic, J., Nikolic, M., Gajic-Veljic, M., et al. (2015) Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Single-Center Experience. International Journal of Dermatology, 54, 978-984.
https://doi.org/10.1111/ijd.12702
|
[12]
|
Sato, S., Kanbe, T., Tamaki, Z., et al. (2018) Clinical Features of Ste-vens-Johnson Syndrome and Toxic Epidermal Necrolysis. Pediatrics International, 60, 697-702. https://doi.org/10.1111/ped.13613
|
[13]
|
Léauté-Labrèze, C., Lamireau, T., Chawki, D., et al. (2000) Diagnosis, Classification, and Management of Erythema Multiforme and Stevens-Johnson Syndrome. Archives of Disease in Childhood, 83, 347-352.
https://doi.org/10.1136/adc.83.4.347
|
[14]
|
Brand, R. and Rohr, J.B. (2000) Toxic Epidermal Necrolysis in Western Australia. The Australasian Journal of Dermatology, 41, 31-33. https://doi.org/10.1046/j.1440-0960.2000.00384.x
|
[15]
|
Koh, M.J. and Tay, Y.K. (2010) Stevens-Johnson Syn-drome and Toxic Epidermal Necrolysis in Asian Children. Journal of the American Academy of Dermatology, 62, 54-60. https://doi.org/10.1016/j.jaad.2009.06.085
|
[16]
|
Chatproedprai, S., Wutticharoenwong, V., Tempark, T., et al. (2018) Clinical Features and Treatment Outcomes among Children with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 20-Year Study in a Tertiary Referral Hospital. Dermatology Research and Practice, 2018, Article ID: 3061084. https://doi.org/10.1155/2018/3061084
|
[17]
|
Brown, K.M., Silver, G.M., Halerz, M., et al. (2004) Toxic Epidermal Necrolysis: Does Immunoglobulin Make a Difference? The Journal of Burn Care & Rehabilitation, 25, 81-88. https://doi.org/10.1097/01.BCR.0000105096.93526.27
|
[18]
|
Shortt, R., Gomez, M., Mittman, N., et al. (2004) Intravenous Immunoglobulin Does Not Improve Outcome in Toxic Epidermal Necrolysis. The Journal of Burn Care & Rehabilitation, 25, 246-255.
https://doi.org/10.1097/01.BCR.0000124746.33279.86
|
[19]
|
Gravante, G., Delogu, D., Marianetti, M., et al. (2007) Toxic Epidermal Necrolysis and Steven Johnson Syndrome: 11-Years Experience and Outcome. European Review for Medical and Pharmacological Sciences, 11, 119-127.
|
[20]
|
Wolkenstein, P., Latarjet, J., Roujeau, J.C., et al. (1998) Randomised Comparison of Thalidomide versus Placebo in Toxic Epidermal Necrolysis. The Lancet (London, England), 352, 1586-1589.
https://doi.org/10.1016/S0140-6736(98)02197-7
|
[21]
|
Viard, I., Wehrli, P., Bullani, R., et al. (1998) Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin. Science (New York, NY), 282, 490-493.
https://doi.org/10.1126/science.282.5388.490
|
[22]
|
Kim, K.J., Lee, D.P., Suh, H.S., et al. (2005) Toxic Epidermal Necrolysis: Analysis of Clinical Course and SCORTEN-Based Comparison of Mortality Rate and Treatment Modalities in Korean Patients. Acta Dermato-Venereologica, 85, 497-502.
|
[23]
|
Huang, Y.C., Chien, Y.N., Chen, Y.T., et al. (2016) Intravenous Immunoglobulin for the Treatment of Toxic Epidermal Necrolysis: A Systematic Review and Meta-Analysis. Giornale Italiano di Dermatologia e Venereologia, 151, 515-524.
|